fenoldopam (Rx)

Brand and Other Names:Corlopam
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 10mg/mL

Severe/Malignant Hypertension, Hypertensive Emergencies

Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous IV infusion  

Titrate by 0.05-0.1 mcg/kg/min q15min or longer until target blood pressure reached; up to 1.6 mcg/kg/min used in clinical trials; may continue maintenance infusion for up to 48 hr

In hospital use only

Monitor

Continuously monitor BP (usually by means of an intra-arterial line) & heart rate

Other Indications & Uses

Short-term (No more than 48 hr adult, 4 hr Peds), in-hospital treatment of

  • Severe or malignant hypertension
  • Hypertensive emergencies

Dosage Forms & Strengths

injectable solution

  • 10mg/mL

Severe/Malignant HTN, Hypertensive Emergencies

Initial 0.2 mcg/kg/min continuous IV infusion pump for <4 hr  

Titrate q20-30min up to 0.3-0.5 mcg/kg/min; not to exceed 0.8 mcg/kg/min

In hospital use only

Monitor

Continuously monitor BP (usually by means of an intra-arterial line) & heart rate

Next:

Interactions

Interaction Checker

and fenoldopam

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (3)

              • lofexidine

                lofexidine, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.

              • metoclopramide intranasal

                metoclopramide intranasal, fenoldopam. dopaminergic effects. Avoid or Use Alternate Drug. Opposing effects of metoclopramide and the interacting drug on dopamine. Potential exacerbation of symptoms (eg, parkinsonian symptoms) or decreased therapeutic effects of metoclopramide.

              • ozanimod

                ozanimod increases toxicity of fenoldopam by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.

              Monitor Closely (14)

              • aldesleukin

                aldesleukin increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

              • amifostine

                amifostine, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.

              • bretylium

                fenoldopam, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.

              • carbidopa

                carbidopa increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.

              • dichlorphenamide

                dichlorphenamide and fenoldopam both decrease serum potassium. Use Caution/Monitor.

              • epoprostenol

                epoprostenol, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

              • hydralazine

                fenoldopam, hydralazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

              • iloprost

                fenoldopam, iloprost. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

              • levodopa

                levodopa increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.

              • maraviroc

                maraviroc, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.

              • minoxidil

                fenoldopam, minoxidil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

              • solriamfetol

                fenoldopam and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              • treprostinil

                fenoldopam, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

              • xipamide

                xipamide increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor.

              Minor (25)

              • acebutolol

                fenoldopam increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • agrimony

                agrimony increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              • atenolol

                fenoldopam increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • betaxolol

                fenoldopam increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • bisoprolol

                fenoldopam increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • brimonidine

                brimonidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              • carvedilol

                fenoldopam increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • celiprolol

                fenoldopam increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • cornsilk

                cornsilk increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              • esmolol

                fenoldopam increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • forskolin

                forskolin increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              • labetalol

                fenoldopam increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • maitake

                maitake increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).

              • metoprolol

                fenoldopam increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • nadolol

                fenoldopam increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • nebivolol

                fenoldopam increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • penbutolol

                fenoldopam increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • pindolol

                fenoldopam increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • propranolol

                fenoldopam increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • reishi

                reishi increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              • shepherd's purse

                shepherd's purse, fenoldopam. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.

              • sotalol

                fenoldopam increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • timolol

                fenoldopam increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

              • tizanidine

                tizanidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

              • treprostinil

                treprostinil increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Angina

              Cardiac dysrhythmia

              Dizziness

              Flushing

              Heart failure

              Hypotension

              Myocardial infarction

              Tachycardia

              Headache

              Nausea

              Vomiting

              Serum creatinine raised

              Postmarketing Reports

              Cardiac disorders: Cardiogenic shock

              Gastrointestinal disorders: Abdominal distension

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity to fenoldopam and sulfite

              Cautions

              Causes a dose-related tachycardia, particularly with infusion rates above 0.1 mcg/kg/min

              Monitor potassium levels

              Increased intraocular pressure in patients with glaucoma or intraocular hypertension

              Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms in susceptible patients

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              There are insufficient data regarding use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

              Severe hypertension can result in maternal stroke, pulmonary edema, myocardial ischemia or death of the mother or fetus

              Animal data

              • In animal studies, there was no evidence of teratogenicity or fetotoxicity when fenoldopam was orally administered to rats and rabbits during organogenesis; there are adverse effects on maternal and fetal outcomes associated with severe hypertension

              Lactation

              There are no data on presence of drug in human milk, effects on breastfed child, or on milk production; drug is present in rat milk; when a drug is present in animal milk, it is likely that the drug will be present in human milk

              Because of potential for severe adverse reactions in breastfed infant, advise women not to breastfeed during treatment

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              D1-dopamine receptor agonist: rapid-acting vasodilator; decreases peripheral resistance and increases renal blood flow; has minimal adrenergic effects

              Also diuretic, natriuretic

              Pharmacokinetics

              Half-Life: 5 min

              Duration: 1-4 hr post infusion

              Onset: initial effect: 10 min, max effect: 30-120 min

              Vd: 0.6 L/kg

              Metabolism: in the liver to a variety of sulfate, glucuronide, & methoxy metabolites

              Metabolite: fenoldopam-8-sulfate, fenoldopam-7-sulfate, fenoldopam glucuronide conjugates, and other minor metabolites

              Excretion: Urine (90%), feces (10%)

              Previous
              Next:

              Administration

              IV Incompatibilities

              Y-site: aminophylline, amphotericin B, ampicillin, bumetanide, cefoxitin, dexamethasone sodium PO4, diazepam, fosphenytoin, furosemide, ketorolac, methohexital, methylprednisolone Na-succinate, pentobarbital, phenytoin, prochlorperazine, Na-bicarb, thiopental

              IV Compatibilities

              Solution: D5W, NS

              Y-site (partial list): alfentanil, atropine, cefazolin, cefepime, ciprofloxacin, cisatracurium, clindamycin, dalfopristin-quinupristin, digoxin, diltiazem, dobutamine, dopamine, epinephrine, erythromycin, esmolol, heparin, hydromorphone, hydroxyzine, linezolid, lorazepam, MgSO4, morphine SO4, mannitol, midazolam, nitroglycerin, KCl, propofol, propranolol, TMP-SMX, vancomycin, verapamil

              IV Preparation

              Adult Infusion: dilute in NS or D5W to a final concentration of 40 mcg/mL; for each 1 mL (=10 mg) of drug use 250 mL diluent

              Pediatric Infusion: dilute in NS or D5W to a final concentration of 60 mcg/mL; for each 1.5 mL (=15 mg) of drug use 250 mL diluent

              IV Administration

              Use diluted solution within 24 hr

              Use continuous infusion pump

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              Corlopam intravenous
              -
              10 mg/mL vial
              Corlopam intravenous
              -
              10 mg/mL vial
              Corlopam intravenous
              -
              10 mg/mL solution
              Corlopam intravenous
              -
              10 mg/mL solution

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Patient Education
              fenoldopam intravenous

              NO MONOGRAPH AVAILABLE AT THIS TIME

              USES: Consult your pharmacist.

              HOW TO USE: Consult your pharmacist.

              SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Consult your pharmacist.

              DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

              NOTES: No monograph available at this time.

              MISSED DOSE: Consult your pharmacist.

              STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

              Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.